ZNF792: A Potential Drug Target and Biomarker (G126375)
ZNF792: A Potential Drug Target and Biomarker
Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in various cellular processes. ZNF792, a ZF protein, is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The ZNF792 Protein
ZNF792 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is composed of a unique N-terminal domain, a transmembrane region, and a C-terminal domain. The C-terminal domain domain is responsible for the formation of a zinc ion-dependent protein-coding region that is involved in protein-protein interactions and may contribute to ZNF792's function.
ZNF792 is a key regulator of various cellular processes, including cell growth, differentiation, and inflammation. It has been shown to play a role in the regulation of gene expression, DNA replication, and chromatin structure. ZNF792 has also been shown to interact with various protein partners, including transcription factors, DNA binding proteins, and chromatin modifiers.
Potential Drug Target
ZNF792 has been identified as a potential drug target due to its involvement in various cellular processes that are implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNF792 has been shown to promote the growth and survival of cancer cells, and it has been used as a biomarker for the evaluation of cancer therapies.
In addition to its role in cancer, ZNF792 has also been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. ZNF792 has been shown to promote the formation of neurofibrillary tangles and to contribute to the misfolding of neurotransmitter- converting proteins, which are hallmarks of neurodegenerative diseases.
In addition to its role in neurodegenerative diseases, ZNF792 has also been implicated in the development and progression of autoimmune disorders. ZNF792 has been shown to promote the development of autoimmune diseases by regulating the function of immune cells and promoting the production of autoantibodies.
Biomarker Potential
ZNF792 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Because it promotes tumor growth and survival, it is used as a biomarker to evaluate the effectiveness of cancer treatments. Furthermore, due to ZNF792's role in neurodegenerative and autoimmune diseases, it has the potential to become a biomarker for these diseases.
Research methods
Currently, researchers are exploring ZNF792's potential as a drug target or biomarker. Researchers are using a variety of techniques, including RNA sequencing and proteomics, to study the functions and interactions of ZNF792. Additionally, researchers are exploring the expression levels of ZNF792 to determine whether it could serve as a biomarker for certain diseases.
Conclusion
ZNF792 is a unique protein that has the potential to serve as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique N-terminal domain, transmembrane region, and C-terminal domain make it an attractive candidate for drug development. Further research is needed to fully understand the functions of ZNF792 and its potential as a drug target or biomarker.
Protein Name: Zinc Finger Protein 792
Functions: May be involved in transcriptional regulation
The "ZNF792 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF792 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843 | ZNF844 | ZNF845 | ZNF846 | ZNF85 | ZNF850 | ZNF852 | ZNF853 | ZNF860 | ZNF862 | ZNF865 | ZNF875 | ZNF876P | ZNF878 | ZNF879 | ZNF880 | ZNF883 | ZNF887P | ZNF888 | ZNF890P | ZNF891 | ZNF90 | ZNF91 | ZNF92 | ZNF93 | ZNF962P | ZNF98 | ZNF99 | ZNFX1 | ZNG1A | ZNG1B | ZNG1C | ZNG1E | ZNG1F | ZNHIT1 | ZNHIT2 | ZNHIT3 | ZNHIT6 | ZNRD2 | ZNRD2-DT | ZNRF1 | ZNRF2 | ZNRF2P1 | ZNRF3 | ZNRF3-AS1 | ZNRF4 | ZP1 | ZP2 | ZP3 | ZP4 | ZPBP | ZPBP2 | ZPLD1 | ZPLD2P | ZPR1 | ZRANB1 | ZRANB2 | ZRANB2-AS1 | ZRANB2-DT | ZRANB3 | ZRS | ZRSR2 | ZRSR2P1 | ZSCAN1
